PDP1是FLT3-ITD阳性急性髓系白血病的关键代谢门控因子和耐药调节因子
该研究探讨FLT3-ITD对急性髓系白血病代谢的影响,发现FLT3-ITD通过RAS信号轴诱导PDP1表达,PDP1增强氧化葡萄糖代谢并促进对FLT3抑制剂quizartinib的耐药,PDP1可能成为AML治疗的潜在靶点。
要点
- FLT3-ITD通过RAS信号轴诱导PDP1表达,增强丙酮酸向三羧酸循环的代谢流。
- PDP1敲低仅抑制FLT3-ITD阳性细胞的增殖并降低其细胞呼吸。
- PDP1过表达增强、PDP1耗竭减弱细胞系及一例AC220耐药AML患者外周原始细胞对AC220的耐药性。
核心结论
- FLT3-ITD确保PDP1表达,PDP1是增强氧化葡萄糖代谢和耐药性的关键代谢调节因子,可能成为AML治疗中可靶向的脆弱点。
研究设计与样本
- 研究采用核磁共振代谢谱分析、内源性标记PDP1结合全基因组CRISPR筛选,并在细胞系及一例AC220耐药AML患者外周原始细胞中验证。
主要发现
- 核磁共振谱显示丙酮酸向三羧酸循环的再分配增强,提示丙酮酸脱氢酶复合体活性增加。
- FLT3-ITD阳性细胞高表达PDP1,全基因组CRISPR筛选揭示FLT3-ITD通过RAS信号轴诱导PDP1表达。
- PDP1敲低降低细胞呼吸,仅损害FLT3-ITD阳性细胞的增殖;这些细胞在缺氧条件下仍依赖PDP1,复氧时表现出PDP1依赖的呼吸能力快速恢复。
- 与FLT3抑制剂quizartinib(AC220)孵育后,PDP1持续存在或上调,导致葡萄糖/丙酮酸代谢进一步向三羧酸循环偏移。
- PDP1过表达增强、PDP1耗竭减弱细胞系及一例AC220耐药AML患者外周原始细胞在体内的AC220耐药性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High metabolic flexibility is pivotal for the persistence and therapy resistance of acute myeloid leukemia (AML). In 20-30% of AML patients, activating mutations of FLT3, specifically FLT3-ITD, are key therapeutic targets. Here, we investigated the influence of FLT3-ITD on AML metabolism. Nuclear Magnetic Resonance (NMR) profiling showed enhanced reshuffling of pyruvate towards the tricarboxylic acid (TCA) cycle, suggesting an increased activity of the pyruvate dehydrogenase complex (PDC). Consistently, FLT3-ITD-positive cells expressed high levels of PDP1, an activator of the PDC. Combining endogenous tagging of PDP1 with genome-wide CRISPR screens revealed that FLT3-ITD induces PDP1 expression through the RAS signaling axis. PDP1 knockdown resulted in reduced cellular respiration thereby impairing the proliferation of only FLT3-ITD cells. These cells continued to depend on PDP1, even in hypoxic conditions, and unlike FLT3-ITD-negative cells, they exhibited a rapid, PDP1-dependent revival of their respiratory capacity during reoxygenation. Moreover, we show that PDP1 modifies the response to FLT3 inhibition. Upon incubation with the FLT3 tyrosine kinase inhibitor quizartinib (AC220), PDP1 persisted or was upregulated, resulting in a further shift of glucose/pyruvate metabolism towards the TCA cycle. Overexpression of PDP1 enhanced, while PDP1 depletion diminished AC220 resistance in cell lines and peripheral blasts from an AC220-resistant AML patient in vivo. In conclusion, FLT3-ITD assures the expression of PDP1, a pivotal metabolic regulator that enhances oxidative glucose metabolism and drug resistance. Hence, PDP1 emerges as a potentially targetable vulnerability in the management of AML.
引用
- Alshamleh I, Kurrle N, Makowka P, et al. PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia. 2023. PMID: 37935978. doi:10.1038/s41375-023-02041-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。